Citations

Clear

1727 citation(s) found for "So, Alan".

A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)
Zirpoli, Gary , McCann, William, McCann, Susan E. , Kelly, Kara M. , Cannioto, Rikki , Sucheston‐Campbell, Lara E. , Stewart, James A. , Hobday, Timothy J. , Salim, Muhammad , Budd, G. Thomas , Albain, Kathy S. , Zirpoli, Gary , Ambrosone, Christine B. , Hutson, Alan D. , Barlow, William E. , Hershman, Dawn L. , Unger, Joseph M. , Moore, Halle C. F. , Isaacs, Claudine , Hortobágyi, Gabriel N. , Gralow, Julie R.

Mayo Clinic

Journal of Clinical Oncology | December 19, 2019 | Volume: 38 | Issue: 8 | Pages: 804-814

10.1200/jco.19.01203 | PMID 31855498 Get It

PURPOSE Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast cancer outcomes. METHODS Patients with breast cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at registration and during treatment (n =1,134). Cox proportional hazards regression adjusting for clinical and lifestyle variables was used. Recurrence and survival were indexed at 6 months after enrollment using a landmark approach. RESULTS There were indications that use of any antioxidant supplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was associated with an increased hazard of recurrence (adjusted hazard ratio [adjHR], 1.41; 95% CI, 0.98 to 2.04; P = .06) and, to a lesser extent, death (adjHR, 1.40; 95% CI, 0.90 to 2.18; P = .14). Relationships with individual antioxidants were weaker perhaps because of small numbers. For nonantioxidants, vitamin B12 use both before and during chemotherapy was significantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01). Use of iron during chemotherapy was significantly associated with recurrence (adjHR, 1.79; 95% CI, 1.20 to 2.67; P < .01) as was use both before and during treatment (adjHR, 1.91; 95% CI, 0.98 to 3.70; P = .06). Results were similar for overall survival. Multivitamin use was not associated with survival outcomes. CONCLUSION Associations between survival outcomes and use of antioxidant and other dietary supplements both before and during chemotherapy are consistent with recommendations for caution among patients when considering the use of supplements, other than a multivitamin, during chemotherapy.
Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study
James, Spencer L , Lucchesi, Lydia R , Bisignano, Catherine, Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Henry, Nathaniel J , McCracken, Darrah, Sylte, Dillon O , Ahmadi, Alireza , Alahdab, Fares , Alipour, Vahid , Andualem, Zewudu , Arabloo, Jalal , Badiye, Ashish , Bagherzadeh, Mojtaba , Banstola, Amrit , Bärnighausen, Till , Barzegar, Akbar , Bayati, Mohsen , Bhaumik, Soumyadeep , Bijani, Ali , Bukhman, Gene , Carvalho, Félix , Crowe, Christopher S. , Dalal, Koustuv , Nasab, Mostafa Dianati, Endries, Aman Yesuf , Fernandes, Eduarda , Fischer, Florian , Fukumoto, Takeshi, Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gilani, Syed Amir , Haagsma, Juanita A., Hostiuc, Sorin , Househ, Mowafa , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Kahsay, Amaha , Kapoor, Neeti , Kasaeian, Amir , Khader, Yousef , Khalil, Ibrahim A, Khan, Ejaz Ahmad , Khazaee-Pool, Maryam , Kokubo, Yoshihiro , Madadin, Mohammed , Majdán, Marek , Maled, Venkatesh , Manafi, Navid , Manafi, Ali, Mangalam, Srikanth , Massenburg, Benjamin B. , Meles, Hagazi Gebre , Menezes, Ritesh G. , Meretoja, Tuomo J , Miazgowski, Bartosz , Miller, Ted R. , Mohammadian-Hafshejani, Abdollah , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Cuong Tat , Nixon, Molly R, Olagunju, Andrew T , Olagunju, Tinuke O , Padubidri, Jagadish Rao , Polinder, Suzanne , Rabiee, Navid , Rahimi‐Movaghar, Vafa , Rawaf, David Laith , Rezapour, Aziz , Rickard, Jennifer , Roro, Elias Merdassa , Roy, Nobhojit , Salamati, Payman, Samy, Abdallah M , Satpathy, Maheswar , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shigematsu, Mika, Tohidinik, Hamid Reza , Valdéz, Pascual , Wijeratne, Tissa , Yisma, Engida , Zaidi, Zoubida , Zhang, Zhi-Jiang, Hay, Simon I , Mokdad, Ali H. , Dianatinasab, Mostafa , Wijeratne, T , Roberts, Nicholas L S , Ahmed, Muktar Beshir , Antonio, Carl Abelardo T. , Daryani, Ahmad , Do, Hoa , Do, Huyen Phuc , Filip, Irina , Fukumoto, Takeshi, Hamidi, Samer , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Khalil, Ibrahim A, Lopez, Alan D , Malekzadeh, Reza , Mohammadpourhodki, Reza , Morrison, Shane D. , Nguyen, Trang Huyen , Rabiee, Mohammad , Radfar, Amir , Rawaf, Salman , Safari‐Faramani, Roya , Salamati, Payman, Sepanlou, Sadaf Ghajarieh , Soheili, Amin , Stokes, Mark Andrew , Tran, Bach Xuan , Zamani, Mohammad , Zhang, Zhi‐Jiang , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | December 19, 2019 | Volume: 26 | Issue: Suppl 2 | Pages: i36-i45

10.1136/injuryprev-2019-043299 | PMID 31857422 Get It

Background Past research has shown how fires, heat and hot substances are important causes of health loss globally. Detailed estimates of the morbidity and mortality from these injuries could help drive preventative measures and improved access to care. Methods We used the Global Burden of Disease 2017 framework to produce three main results. First, we produced results on incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years from 1990 to 2017 for 195 countries and territories. Second, we analysed these results to measure mortality-to-incidence ratios by location. Third, we reported the measures above in terms of the cause of fire, heat and hot substances and the types of bodily injuries that result. Results Globally, there were 8 991 468 (7 481 218 to 10 740 897) new fire, heat and hot substance injuries in 2017 with 120 632 (101 630 to 129 383) deaths. At the global level, the age-standardised mortality caused by fire, heat and hot substances significantly declined from 1990 to 2017, but regionally there was variability in age-standardised incidence with some regions experiencing an increase (eg, Southern Latin America) and others experiencing a significant decrease (eg, High-income North America). Conclusions The incidence and mortality of injuries that result from fire, heat and hot substances affect every region of the world but are most concentrated in middle and lower income areas. More resources should be invested in measuring these injuries as well as in improving infrastructure, advancing safety measures and ensuring access to care.
A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain
Grider, Jay S., Lamer, Tim J. , Pope, Jason E. , Falowski, Steven , Hunter, Corey , Russo, Marc , Carayannopoulos, Alexios G. , Shah, Jay M., Harned, Michael , Bolash, Robert , Arle, Jeff, Kapural, Leo, Amirdelfan, Kasra , Jain, Sameer , Liem, Liong, Carlson, Jonathan D. , Malinowski, Mark N. , Bendel, Markus A. , Yang, Ajax , Aiyer, Rohit , Valimahomed, Ali, Antony, Ajay, Craig, Justin, Al‐Kaisy, Adnan , Christelis, Nick , Rosenquist, Richard W. , Levy, Robert M. , Bendel, Markus, Deer, Timothy R. , Grider, Jay S. , Provenzano, David , Slavin, Konstantin V. , Hagedorn, Jonathan M. , Fishman, Michael Alan , Mekhail, Nagy

Mayo Clinic

Pain Medicine | December 18, 2019 | Volume: 21 | Issue: 7 | Pages: 1421-1432

10.1093/pm/pnz353 | PMID 32034422 Get It

AbstractObjectiveTo conduct a systematic literature review of spinal cord stimulation (SCS) for pain.DesignGrade the evidence for SCS.MethodsAn international, interdisciplinary work group conducted literature searches, reviewed abstracts, and selected studies for grading. Inclusion/exclusion criteria included randomized controlled trials (RCTs) of patients with intractable pain of greater than one year’s duration. Full studies were graded by two independent reviewers. Excluded studies were retrospective, had small numbers of subjects, or existed only as abstracts. Studies were graded using the modified Interventional Pain Management Techniques–Quality Appraisal of Reliability and Risk of Bias Assessment, the Cochrane Collaborations Risk of Bias assessment, and the US Preventative Services Task Force level-of-evidence criteria.ResultsSCS has Level 1 evidence (strong) for axial back/lumbar radiculopathy or neuralgia (five high-quality RCTs) and complex regional pain syndrome (one high-quality RCT).ConclusionsHigh-level evidence supports SCS for treating chronic pain and complex regional pain syndrome. For patients with failed back surgery syndrome, SCS was more effective than reoperation or medical management. New stimulation waveforms and frequencies may provide a greater likelihood of pain relief compared with conventional SCS for patients with axial back pain, with or without radicular pain.
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Shrader, Peter, Pieper, Karen S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Singer, Daniel E. , Go, Alan S. , Piccini, Jonathan P. , Patients, *On behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) I & II Investigators and, Freeman, James V. , Allen, Larry A. , Chan, Paul S. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Hylek, Elaine M. , Steinberg, Benjamin A. , Peterson, Eric D. , Patients, *On behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) I & II Investigators and

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 13, 2019 | Volume: 12 | Issue: 12 | Pages: No page available

10.1161/circep.119.007612 | PMID 31830822 Get It

Background: Studies evaluating the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outcomes have shown mixed results. In addition, guidelines recommend continuing oral anticoagulation (OAC) after ablation for those at risk of stroke, but real-world data are lacking. Methods: We evaluated outcomes including death, myocardial infarction, stroke or systemic embolism, intracranial bleeding, major bleeding, and hospitalization in patients undergoing AF ablation compared with a propensity score matched cohort of patients treated with anti-arrhythmic medications only in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation registries. Cox proportional hazards regression was performed to evaluate the association between AF ablation and outcomes. We then evaluated patterns of treatment with OAC among AF ablation patients. Results: Among 21 595 patients, 1190 (6%) underwent de novo AF ablation. Our propensity score-matched cohort included 1087 patients who underwent AF ablation matched 1:1 with 1087 patients treated with antiarrhythmic medications only. There were no significant differences in the risk of all-cause and cardiovascular death, and most other major adverse cardiovascular and neurological events. AF catheter ablation was associated with an increased risk of all-cause hospitalization during follow-up (hazard ratio, 1.24 [95% CI, 1.05–1.46]), particularly in the first 3 months (the standard blanking period) after the procedure. Among those who underwent AF ablation with a CHA 2 DS 2 VASc score ≥2 for men and ≥3 for women, 23% had OAC discontinued after ablation. Among those who discontinued OAC, the median time to discontinuation was 6.2 months. Conclusions: In this large US national registry, we found no difference in adjusted rates of cardiovascular or all-cause death between patients treated with AF catheter ablation and antiarrhythmic medications only. Notably, discontinuation of OAC after ablation remains relatively common despite guideline recommendations for continued stroke prevention therapy in patients at risk of stroke.
Modafinil for people with schizophrenia or related disorders
Ortiz‐Orendain, Javier , Covarrubias-Castillo, Sergio Armando, Vázquez‐Álvarez, Alan Omar , Castiello, Santiago , Quiñones, Gustavo E Arias, Seegers, Maya, Colunga‐Lozano, Luis Enrique , Colunga-Lozano, Luis E , Quiñones, Gustavo E. Arias

Mayo Clinic

Cochrane Database of Systematic Reviews | December 11, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd008661.pub2 | PMID 31828767 Get It

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF
Goto, Shinichi, Goto, Shinya , Goto, Shinya, Goto, Shinya, Pieper, Karen S. , Bassand, Jean‐Pierre , Camm, Alan John, Fitzmaurice, David , Goldhaber, Samuel Z, Haas, Sylvia, Parkhomenko, Alexander, Oto, Ali, Misselwitz, Frank , Turpie, Alexander G G, Verheugt, F.W.A., Fox, Keith A A, Kakkar, Ajay K. , Parkhomenko, Alexander , Goldhaber, Samuel Z. , Oto, Ali̇ , Turpie, Alexander G.G., Gersh, Bernard J.

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | December 5, 2019 | Volume: 6 | Issue: 5 | Pages: 301-309

10.1093/ehjcvp/pvz076 | PMID 31821482 Get It

Abstract Aims Most clinical risk stratification models are based on measurement at a single time-point rather than serial measurements. Artificial intelligence (AI) is able to predict one-dimensional outcomes from multi-dimensional datasets. Using data from Global Anticoagulant Registry in the Field (GARFIELD)-AF registry, a new AI model was developed for predicting clinical outcomes in atrial fibrillation (AF) patients up to 1 year based on sequential measures of prothrombin time international normalized ratio (PT-INR) within 30 days of enrolment. Methods and results Patients with newly diagnosed AF who were treated with vitamin K antagonists (VKAs) and had at least three measurements of PT-INR taken over the first 30 days after prescription were analysed. The AI model was constructed with multilayer neural network including long short-term memory and one-dimensional convolution layers. The neural network was trained using PT-INR measurements within days 0–30 after starting treatment and clinical outcomes over days 31–365 in a derivation cohort (cohorts 1–3; n = 3185). Accuracy of the AI model at predicting major bleed, stroke/systemic embolism (SE), and death was assessed in a validation cohort (cohorts 4–5; n = 1523). The model’s c-statistic for predicting major bleed, stroke/SE, and all-cause death was 0.75, 0.70, and 0.61, respectively. Conclusions Using serial PT-INR values collected within 1 month after starting VKA, the new AI model performed better than time in therapeutic range at predicting clinical outcomes occurring up to 12 months thereafter. Serial PT-INR values contain important information that can be analysed by computer to help predict adverse clinical outcomes.
Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Mehrotra, Shailly , Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Lad, Thomas E. , Velasco, Mario R. , Overmoyer, Beth , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao , Sharma, Manish R.

Mayo Clinic

The Journal of Clinical Pharmacology | December 5, 2019 | Volume: 60 | Issue: 4 | Pages: 444-452

10.1002/jcph.1559 | PMID 31802506 Get It

AbstractChemotherapy‐induced peripheral neuropathy (henceforth, neuropathy) is often dose limiting and is generally managed by empirical dose modifications. We aimed to (1) identify an early time point that is predictive of future neuropathy using a patient‐reported outcome and (2) propose a dose‐adjustment algorithm based on simulated data to manage neuropathy. In previous work, a dose‐neuropathy model was developed using dosing and patient‐reported outcome data from Cancer and Leukemia Group B 40502 (Alliance), a randomized phase III trial of paclitaxel, nanoparticle albumin–bound paclitaxel or ixabepilone as first‐line chemotherapy for locally recurrent or metastatic breast cancer. In the current work, an early time point that is predictive of the future severity of neuropathy was identified based on predictive accuracy of the model. Using the early data and model parameters, simulations were conducted to propose a dose‐adjustment algorithm for the prospective management of neuropathy in individual patients. The end of the first 3 cycles (12 weeks) was identified as the early time point based on a predictive accuracy of 75% for the neuropathy score after 6 cycles. For paclitaxel, nanoparticle albumin–bound paclitaxel, and ixabepilone, simulations with the proposed dose‐adjustment algorithm resulted in 61%, 48%, and 35% fewer patients, respectively, with neuropathy score ≥8 after 6 cycles compared to no dose adjustment. We conclude that early patient‐reported outcome data on neuropathy can be used to guide dose adjustments in individual patients that reduce the severity of future neuropathy. Prospective validation of this approach should be undertaken in future studies.
Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation
Benjamin, Emelia J. , Buxton, Alfred E. , Calkins, Hugh , Chung, Mina K. , Curtis, Anne B. , Desvigne‐Nickens, Patrice , Packer, Douglas L. , Piccini, Jonathan P. , Rosenberg, Yves , Russo, Andrea M. , Wang, Paul J. , Cooper, Lawton S. , Go, Alan S. , Marrouche, Nassir F. , Hills, Melanie True, Zieman, Susan J., Benjamin, Emelia J , Al‐Khatib, Sana M. , Jaı̈s, Pierre , Healey, Jeff S. , Link, Mark S. , Noseworthy, Peter A. , Sanders, Prashanthan , Yao, Xiaoxi

Mayo Clinic

Circulation | November 20, 2019 | Volume: 141 | Issue: 6 | Pages: 482-492

10.1161/circulationaha.119.042706 | PMID 31744331 Get It

Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ablation significantly reduced cardiovascular hospitalizations. Despite the existing data on AF catheter ablation, numerous knowledge gaps remain concerning this intervention. This report is based on a recent virtual workshop convened by the National Heart, Lung, and Blood Institute to identify key research opportunities in AF ablation. We outline knowledge gaps related to emerging technologies, the relationship between cardiac structure and function and the success of AF ablation in patient subgroups in whom clinical benefit from ablation varies, and potential platforms to advance clinical research in this area. This report also considers the potential value and challenges of a sham ablation randomized trial. Prioritized research opportunities are identified and highlighted to empower relevant stakeholders to collaborate in designing and conducting effective, cost-efficient, and transformative research to optimize the use and outcomes of AF ablation.
A Comparison of Revision Rates and Patient-Reported Outcomes for a 2-Level Posterolateral Fusion Augmented With Single Versus 2-Level Transforaminal Lumbar Interbody Fusion
Kaye, I. David , Fang, Terry, Wagner, Scott C. , Butler, Joseph S. , Sebastian, Arjun S. , Morrissey, Patrick B. , Levine, Marc J., Vaccaro, Alexander R. , Hilibrand, Alan S. , Sebastian, Arjun, Vaccaro, Alex R , Fang, Terry, Levine, Marc J.

Mayo Clinic

Global Spine Journal | November 20, 2019 | Volume: 10 | Issue: 8 | Pages: 958-963

10.1177/2192568219889360 | PMID 32875833 Get It

Study Design: Retrospective, single institution, multisurgeon case control series. Objective: To determine whether there are differences in reoperation rates or outcomes for patients undergoing 2-level posterolateral fusion (PLF) augmented by a transforaminal lumbar interbody fusion (TLIF) at only one of the levels or at both. Methods: A total of 416 patients were identified who underwent 2-level PLF with a TLIF at either one of those levels (n = 183) or at both (n = 233) with greater than 1-year follow-up. Demographic, surgical, radiographic, and clinical data was reviewed for each patient. These included age, sex, race, body mass index, smoking status, Charleston Comorbidity Index, operative time, estimated blood loss, length of stay, and patient-reported outcome measures. Results: Each cohort underwent 24 reoperations. Although the number of overall reoperations was not significantly different ( P > .05), among the reoperation types, there were significantly more reoperations for adjacent segment disease in the 2-level group compared to the 1-level group (19 vs 12, P = .04). There was no difference in reoperation for pseudarthrosis between the groups ( P > .05). Although both groups experienced significant improvements in Oswestry Disability Index ( P < .001) and Short Form–12 health questionnaire ( P < .001), there were no differences between improvements for 1- versus 2-level cohorts. Conclusions: For patients undergoing 2-level PLF in the setting of a TLIF, using a TLIF at one versus both levels does not seem to influence reoperation rates or outcomes. However, reoperation rates for adjacent segment disease are increased in the setting of a 2-level PLF augmented by a 2-level TLIF.